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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to beta-
galactosidase from Streptococcus thermophilus and reduction of 




EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a 
health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and 
reduction of gastrointestinal discomfort. According to the applicant, the food constituent which is the subject of 
the claim is beta-galactosidase from Streptococcus thermophilus. Streptococcus thermophilus is added to infant 
formulae in the production process for fermentation purposes and the live organisms are inactivated after the 
fermentation process. The Panel considers that the food constituent, beta-galactosidase from Streptococcus 
thermophilus, under the conditions of use proposed by the applicant, is sufficiently characterised. The claimed 
effect proposed by the applicant is “reduction of gastro-intestinal discomfort”. The target population proposed by 
the applicant is infants and young children. The Panel considers that reduction of gastrointestinal discomfort is a 
beneficial physiological effect. No human studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect 
relationship has not been established between the consumption of beta-galactosidase which is produced by 
Streptococcus thermophilus (subsequently inactivated) during fermentation of an infant formula and reduction of 
gastrointestinal discomfort. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for 
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to beta-
galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
According to the applicant, the food constituent which is the subject of the claim is “microbial beta-
galactosidase present as an endogenous component of some infant nutrition products”. Following a 
request for clarification from EFSA during the validation period of the application, the applicant 
explained that the food constituent which is the subject of the claim is beta-galactosidase from 
Streptococcus thermophilus. Streptococcus thermophilus is added to infant formulae in the production 
process for fermentation purposes and the live organisms are inactivated after the fermentation 
process. The Panel considers that the food constituent, beta-galactosidase from Streptococcus 
thermophilus, under the conditions of use proposed by the applicant, is sufficiently characterised. 
The claimed effect proposed by the applicant is “reduction of gastro-intestinal discomfort”. The target 
population proposed by the applicant is infants and young children. The Panel considers that reduction 
of gastrointestinal discomfort is a beneficial physiological effect. 
The Panel notes that no human studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of beta-galactosidase which is produced by Streptococcus thermophilus (subsequently 
inactivated) during fermentation of an infant formula and reduction of gastrointestinal discomfort. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of permitted 
claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 14/02/2008. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 26/03/2008 and on 29/11/2013, during the validation process of the application, EFSA sent a 
request to the applicant to provide missing information. 
 On 12/08/2013 and on 21/01/2014, respectively, EFSA received the missing information as 
submitted by the applicant. 
 The scientific evaluation procedure started on 23/01/2014. 
 On 06/03/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions for 
the applicant to provide additional information to accompany the application. The clock was 
stopped on 11/03/2014 and was restarted on 04/07/2014, in compliance with Article 16(1) of 
Regulation (EC) No 1924/2006>. 
 On 04/07/2014, EFSA received the requested information (which was made available to EFSA in 
electronic format on 01/07/2014). 
 During its meeting on 18/09/2014, the NDA Panel, having evaluated the data submitted, adopted 
an opinion on the scientific substantiation of a health claim related to beta-galactosidase from 
Streptococcus thermophilus and reduction of gastrointestinal discomfort. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on 
the scientific substantiation of a health claim related to: beta-galactosidase from Streptococcus 
thermophilus and reduction of gastrointestinal discomfort. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of “beta-galactosidase from Streptococcus thermophilus”, a positive assessment of its safety, nor a 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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decision on whether “beta-galactosidase from Streptococcus thermophilus” is, or is not, classified as a 
foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation 
(EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Specialised Nutrition Europe (formerly IDACE), 9-31 Avenue des 
Nerviens, 1040 Brussels, Belgium. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent which is the subject of the claim is “microbial beta-
galactosidase present as an endogenous component of some infant nutrition products”. In response to a 
request by EFSA for clarification, the applicant explained that the food which is the subject of the 
claim is beta-galactosidase from Streptococcus thermophilus. Streptococcus thermophilus is added to 
formulae in the production process for fermentation purposes and is subsequently inactivated. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect refers to the reduction of gastrointestinal discomfort. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Lactase for comfortable 
digestion”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is infants and young children between birth and three 
years. In a response to a request by EFSA for clarification, the applicant indicated that the effect is 
expected to occur in infants and young children suffering from transient lactase deficiency owing to 
the damage of intestinal cells, caused by inflammation, allergic reactions or infections, resulting in a 
reduction of lactase activity. 
The applicant has proposed an intake of beta-galactosidase of at least 135 U/day in lactase 
supplements, 18 U/100 mL in infant and follow-on formula. 
ASSESSMENT 
1. Characterisation of the food/constituent 
According to the applicant, the food constituent which is the subject of the claim is “microbial beta-
galactosidase present as an endogenous component of some infant nutrition products”. Following a 
request for clarification from EFSA during the validation period of the application, the applicant 
explained that the food constituent which is the subject of the claim is beta-galactosidase from 
Streptococcus thermophilus. Streptococcus thermophilus is added to infant formulae in the production 
process for fermentation purposes and the live organisms are inactivated after the fermentation 
process. 
For the scientific substantiation of the claim, the applicant provided one human intervention study 
which investigated the effect of an infant formula fermented with Streptococcus thermophilus and 
Bifidobacterium breve and thickened with maize and potato starch compared with an unfermented 
infant formula with no added starch. 
During the stop-the-clock procedure, EFSA informed the applicant that, in the context of the 
information provided, EFSA would consider the food which is the subject of the claim to be the 
specific infant formula produced with Streptococcus thermophilus producing beta-galactosidase and 
asked the applicant to provide further details to allow the characterisation of the formula. In particular, 
the applicant was asked to consider that during the fermentation process, and the process of 
inactivation of the bacterium, constituents other than beta-galactosidase are produced and also that no 
studies had been provided which allowed an assessment of an independent effect of beta-galactosidase 
from Streptococcus thermophilus. 
Beta-galactosidase from Streptococcus thermophilus and gastrointestinal discomfort 
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In reply, the applicant maintained that the food constituent which is the subject of the claim is beta-
galactosidase from Streptococcus thermophilus and informed EFSA that the applicant “did not 
consider it relevant to characterise the amount of Streptococcus added before fermentation, nor the 
fermentation process, as the resulting amount of beta-galactosidase in the end product was the claimed 
constituent”. 
The Panel notes that beta-galactosidase, which is produced by Streptococcus thermophilus 
(subsequently inactivated) during fermentation of an infant formula, is a well-characterised enzyme 
and its activity can be measured in foods by established methods. 
The Panel considers that beta-galactosidase from Streptococcus thermophilus, under the conditions of 
use proposed by the applicant, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect is “reduction of gastro-intestinal discomfort”. The target population proposed by 
the applicant is infants and young children. 
Unexplained bouts of crying in young infants, traditionally, have been attributed to gastrointestinal 
disturbances and pain (Shamir et al., 2013). A specific term, infant colic, is commonly used to reflect 
this situation in young infants. However, there is no proof that crying in infant colic is caused by pain 
in the abdomen or any other body part. Infant colic has been included in the list of childhood 
functional gastrointestinal disorders of the Rome III Coordinating Committee with diagnostic criteria 
based on infant crying time (Hyman et al., 2006). Infant pain and discomfort behaviours can also be 
measured objectively using validated pain scales and infant distress behaviour can be assessed by 
trained observers using behaviour logs or rating scales, supported by evidence for their validity 
(Shamir et al., 2013). The Rome III criteria and validated tools can be used to assess gastrointestinal 
discomfort in infants once other causes of crying, pain or distress have been excluded. 
The Panel considers that the reduction of gastrointestinal discomfort is a beneficial physiological 
effect. 
3. Scientific substantiation of the claimed effect 
The applicant stated that a literature search was performed using the following key words: “beta-
galactosidase” AND “infant” AND “crying”, and that inclusion criteria comprised intervention studies 
in infants and young children in which lactase was administered and the effects on colic, flatulence, 
bloating or crying time were studied. No information was provided on the database which was used 
for the search, nor on the time limits of the search. 
Through this literature search the applicant identified three human intervention studies (Kearney et al., 
1998; Kanabar et al., 2001; Roy et al., 2004). 
The study by Roy et al. (2004) investigated the effects of an infant formula fermented with 
Streptococcus thermophilus and Bifidobacterium breve, both of which can produce beta-galactosidase, 
and thickened with maize and potato starch, compared with an unfermented infant formula with no 
added starch. The Panel notes that this study does not allow the assessment of an independent effect of 
beta-galactosidase from Streptococcus thermophilus and considers that no conclusions can be drawn 
from this study for the scientific substantiation of the claim. 
In the two other studies (Kearney et al., 1998; Kanabar et al., 2001), which were provided as 
supportive evidence by the applicant, beta-galactosidase other than beta-galactosidase from 
Streptococcus thermophilus was added to infant formulae before feeding. The Panel considers that no 
conclusions can be drawn from these studies in relation to a claim on beta-galactosidase from 
Streptococcus thermophilus. 
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The Panel notes that no human studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of beta-galactosidase which is produced by Streptococcus thermophilus (subsequently 
inactivated) during fermentation of an infant formula and reduction of gastrointestinal discomfort. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, beta-galactosidase from Streptococcus thermophilus, under the 
conditions of use proposed by the applicant, is sufficiently characterised. 
 The claimed effect proposed by the applicant is “reduction of gastro-intestinal discomfort”. 
The target population proposed by the applicant is infants and young children. Reduction of 
gastrointestinal discomfort is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of beta-
galactosidase which is produced by Streptococcus thermophilus (subsequently inactivated) 
during fermentation of an infant formula and reduction of gastrointestinal discomfort. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on beta-galactosidase from Streptococcus thermophilus and reduction of 
gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 
0068_FR). January 2014. Submitted by Specialised Nutrition Europe (SNE). 
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